Page 38 - Read Online
P. 38

Politei et al. Rare Dis Orphan Drugs J 2024;3:10  https://dx.doi.org/10.20517/rdodj.2023.46   Page 5 of 12



















                Figure 3. (A) Examination of a hemicolectomy specimen from a female Fabry patient as a result of diverticular perforation. Photo
                property of Dr. Politei. Published with permission of Dr. Politei. (B) Examination of a colectomy specimen from a male Fabry patient
                with diverticular disease. Partial sigmoid resection due to multiple episodes of diverticulitis. Photo property of Dr. Politei. Published with
                permission of Dr. Politei.


               reduction has led to the suspicion of “intestinal angina”, being the reason for the abdominal cramps after
               meals.

               All these alterations of intestinal motility predispose to bacterial overgrowth and subsequent sustained
               diarrhea, malabsorption, and diverticula formation . Bile salt breath tests for expiration  or aspiration of
                                                                                          [24]
                                                          [10]
               jejunal content  confirm this finding. In addition to bacterial overgrowth, new evidence suggests that
                            [7]
               globotriaosylsphingosine (lysoGL-3) directly influences microbiotical growth, potentially culminating in
                                                                 [30]
               dysbiosis and a disproportion of the intestinal microbiota . Dysbiosis is associated with the activation of
               proinflammatory immune responses due to an abnormal proliferation of immune cells and increases the
               production of proinflammatory compounds such as lipopolysaccharides . Furthermore, gut dysbiosis
                                                                               [31]
               compromises the energy supply to the colonic epithelium and elevates epithelial permeability, resulting in a
               “leaky gut” [4,32] . In this context, lysoGL-3 increases the biofilm-forming capacity of several individual
               bacteria, including Bacteroides fragilis . LysoGL-3 also alters the bacterial conformation of human gut
                                                [30]
               microbiota suspensions, increasing bacterial counts of B. fragilis, and influencing the production of short-
                                                                                [30]
               chain fatty acids, resulting in a notable reduction in butyrate concentration . These results were recently
               replicated , where dysbiotic features imply a disruption of colon homeostasis, leading to accelerated
                       [33]
               intestinal transit, visceral hypersensitivity, and impaired communication along the gut-brain axis in the
               mouse model.

               DIAGNOSIS OF GASTROINTESTINAL INVOLVEMENT IN FABRY DISEASE
               Misinterpretation of gastrointestinal manifestations is commonly reported in patients with FD. The most
               frequent misdiagnoses are irritable bowel syndrome, chronic inflammatory bowel disease, appendicitis,
               autoimmune disorders, Whipple’s disease, dermatomyositis, or somatoform disorder . Exceptionally, FD
                                                                                        [34]
               may co-occur with other gastrointestinal diseases such as Crohn’s disease, coeliac disease, or colon
                     [10]
               cancer . Previously, the assessment of gastrointestinal signs and symptoms in Fabry patients relied on
               patient interviews and tools designed for other gastrointestinal disorders, including the Gastrointestinal
               Symptom Rating Scale (GSRS) and Rome III criteria (now Rome IV) . Evaluating GI symptoms in Fabry
                                                                          [12]
               patients using questionnaires based on the Rome III criteria, it was found that 16 out of 25 adult and 2 out
               of 8 pediatric Fabry patients, all experiencing GI symptoms, exhibited a symptom profile resembling that of
               functional gastrointestinal disorders . The 24-h and 7-day Fabry disease patient-reported outcome-
                                               [35]
               gastrointestinal (FABPRO-GI) assessments represent the first FD-specific Patient-Reported Outcomes
               (PROs) designed to evaluate GI signs and symptoms in FD patients . Given the paucity of PROs tailored
                                                                         [36]
               for FD, the 24-h and 7-day FABPRO-GI instruments present an opportunity to gain new insights into Fabry
   33   34   35   36   37   38   39   40   41   42   43